In the first half of 2025, Mark Cuban’s Cost Plus Drugs Co. has expanded operations across its drug manufacturing, distribution and partnership enterprises.
The company continues to grow its presence in the generic drug market while also working to promote transparency in the pharmaceutical supply chain.
Here are five notable moves involving the company:
- In May, Cost Plus Drugs was among four partners in Equip-A-Pharma, a White House initiative to help bolster on-site drug manufacturing. The company will deploy an AI-enabled automated platform to produce more active pharmaceutical ingredients such as lidocaine and diltiazem.
- Mr. Cuban said the company now has more than 25 partnerships with pass-through pharmacy benefit managers, with plans to grow in 2025. The collaborations aim to help plan sponsors lower drug spending and improve patient outcomes by aligning incentives with stakeholders.
- The company also expects to expand its biosimilar offerings in 2025, further challenging incumbent pharmaceutical firms in the high-cost biologics space.
- In a push for transparency, Mr. Cuban said Cost Plus Drugs will begin posting its Cost Plus Wellness Direct contracts online, allowing other organizations to learn from and leverage them.
- The company’s Affiliate Pharmacy Network is also growing. Launched in 2023, the network now supports independent and grocery chain pharmacies, using the “Team Cuban Card,” and works to provide transparent pricing on more than 2,000 drugs.
